CHECK CAP LTD (CHEK) Stock Overview
USA - NASDAQ:CHEK - IL0011336851 - Common Stock
CHEK Key Statistics, Chart & Performance
The current stock price of CHEK is 1.62 USD. In the past month the price decreased by -26.7%. In the past year, price increased by 40.93%.
CHEK Latest News, Press Relases and Analysis
CHEK Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABT | ABBOTT LABORATORIES | 25.42 | 220.78B | ||
| ISRG | INTUITIVE SURGICAL INC | 63.47 | 195.91B | ||
| BSX | BOSTON SCIENTIFIC CORP | 34.27 | 149.82B | ||
| SYK | STRYKER CORP | 29.71 | 145.96B | ||
| MDT | MEDTRONIC PLC | 16.94 | 120.15B | ||
| BDX | BECTON DICKINSON AND CO | 13.02 | 53.26B | ||
| IDXX | IDEXX LABORATORIES INC | 53.36 | 51.27B | ||
| EW | EDWARDS LIFESCIENCES CORP | 29.61 | 44.68B | ||
| RMD | RESMED INC | 27.17 | 37.87B | ||
| GEHC | GE HEALTHCARE TECHNOLOGY | 16.77 | 35.68B | ||
| PHG | KONINKLIJKE PHILIPS NVR- NY | 17.26 | 27.76B | ||
| DXCM | DEXCOM INC | 41.37 | 27.58B |
Related stock screener links
About CHEK
Company Profile
Check-Cap Ltd. is a clinical stage medical diagnostics company, which engages in the development of ingestible imaging capsule systems for colorectal cancer screening. Check Cap Ltd develops C-Scan, patient-friendly preparation-free test designed to detect polyps before they may transform into cancer to enable early intervention and cancer prevention. It's capsule-based screening technology aims to increase screening adherence worldwide. The system utilizes ultra-low-dose X- rays to scan the inner lining of the colon for precancerous polyps, and other structural abnormalities. C-Scan is non-invasive capsule that is propelled through the gastrointestinal tract by natural motility. C-Scan is comprised of three main components: C-Scan Cap, an ingestible X-ray scanning capsule; C-Scan Track, three miniaturized patches worn on the patient’s back for integrated positioning, control and data recording; and C-Scan View, a proprietary software to process and represent 2D and 3D maps of the inner surface of the colon.
Company Info
CHECK CAP LTD
29 Abba Hushi Ave., P.O.Box 1271, Isfiya
Isfiya 3009000 IL
CEO: Alex Ovadia
Employees: 85
Phone: 97248303401
CHECK CAP LTD / CHEK FAQ
Can you describe the business of CHECK CAP LTD?
Check-Cap Ltd. is a clinical stage medical diagnostics company, which engages in the development of ingestible imaging capsule systems for colorectal cancer screening. Check Cap Ltd develops C-Scan, patient-friendly preparation-free test designed to detect polyps before they may transform into cancer to enable early intervention and cancer prevention. It's capsule-based screening technology aims to increase screening adherence worldwide. The system utilizes ultra-low-dose X- rays to scan the inner lining of the colon for precancerous polyps, and other structural abnormalities. C-Scan is non-invasive capsule that is propelled through the gastrointestinal tract by natural motility. C-Scan is comprised of three main components: C-Scan Cap, an ingestible X-ray scanning capsule; C-Scan Track, three miniaturized patches worn on the patient’s back for integrated positioning, control and data recording; and C-Scan View, a proprietary software to process and represent 2D and 3D maps of the inner surface of the colon.
Can you provide the latest stock price for CHECK CAP LTD?
The current stock price of CHEK is 1.62 USD. The price increased by 5.19% in the last trading session.
Does CHECK CAP LTD pay dividends?
CHEK does not pay a dividend.
What is the ChartMill technical and fundamental rating of CHEK stock?
CHEK has a ChartMill Technical rating of 6 out of 10 and a ChartMill Fundamental rating of 0 out of 10.
Can you provide the sector and industry classification for CHECK CAP LTD?
CHECK CAP LTD (CHEK) operates in the Health Care sector and the Health Care Equipment & Supplies industry.
Is CHECK CAP LTD (CHEK) stock a good buy?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on CHEK.
CHEK Technical Analysis
ChartMill assigns a technical rating of 6 / 10 to CHEK. When comparing the yearly performance of all stocks, CHEK is one of the better performing stocks in the market, outperforming 94.84% of all stocks.
CHEK Financial Highlights
Over the last trailing twelve months CHEK reported a non-GAAP Earnings per Share(EPS) of -4.3. The EPS decreased by -43.15% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -6670.82% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |